– USA, MD – MaxCyte, Inc., (Nasdaq: MXCT / LON: MXCT), a leading, cell-engineering-focused company, announced the appointment of Cynthia Collins to its Board as a non-executive director, effective October 14, 2024, increasing the Board to 10 members.
“I am pleased to welcome Cynthia to MaxCyte’s Board of Directors,” said Maher Masoud, President and CEO of MaxCyte. “Cynthia has extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years. I look forward to working alongside her to enable a growing set of next-generation cell therapies as the premier cell engineering platform in our industry.”
Cynthia Collins will also join the compensation committee.
About Cynthia Collins
Cynthia Collins brings over 40 years of experience in the biotechnology industry and cell and gene medicines to MaxCyte, including her most recent role as CEO of Editas Medicine, where she was involved in dosing the first patient ever with an in-vivo gene-modified therapy. Previously, Ms. Collins served as CEO of Human Longevity Inc., CEO/GM of General Electric Healthcare’s Cell Therapy and Lab Businesses, and CEO of GenVec, Inc., a vaccine and gene therapy company.
Cynthia Collins serves as a member of the Board of Directors of several healthcare companies, including Alanis Therapeutics, Nutcracker Therapeutics, Poseida Therapeutics (Nasdaq: PSTX), Certara (Nasdaq: CERT), DermTech (OTC: DMTKQ), Draper Laboratory, and Panavance Therapeutics. She is also a board member of the Foundation for mRNA Medicines.
“I am honored to join MaxCyte’s Board of Directors, where I believe there is exceptional work being done to propel the cell and genetic medicine industry forward,” said Cynthia Collins. “I am excited to support the Company’s growth and innovation as they continue to help developers bring a new class of therapies to market.”
Cynthia Collins holds a Bachelor of Science degree in Microbiology from the University of Illinois, Urbana, and an MBA from The University of Chicago Booth School of Business.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx, and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical, and regulatory support, we aim to guide them on their journey to transform human health.
For more: https://maxcyte.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.